Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Exciting results for BCMA/CD3 bispecific PF-3135 in R/R MM

Noopur Raje • 7 Dec 2019
ASH 2019
Multiple Myeloma Antibodies PF-3135

PF-06863135 (PF-3135) is a bispecific, humanized, monoclonal antibody consisting of BCMA and CD3-targeting arms paired on an IgG2a backbone by hinge-mutation technology. Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the dose-escalation portion of an ongoing phase I study (NCT03269136) of PF-3135 in patients with relapsed/refractory multiple myeloma (MM). Early data show that treatment with intravenous PF-3135 was well tolerated at the dose levels evaluated. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Noopur Raje

2:06
Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma
Noopur Raje • 29 Sep 2023
2:35
Recommendations for managing infections in patients with myeloma treated with bispecifics
Noopur Raje • 29 Sep 2023
1:13
The role of checkpoint inhibitors in multiple myeloma & future considerations for these agents
Noopur Raje • 29 Sep 2023
2:17
Session highlights: practical aspects of immunotherapy in multiple myeloma
Noopur Raje • 29 Sep 2023

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals